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Abstract The oral bioavailability of poorly water soluble
drug can be improved using nanosuspension. Nanosus-
pensions are fine dispersion of uniform-sized solid particles
in an aqueous vehicle. The present work is aimed at the
formulation and evaluation of nanosuspension of felodip-
ine, a poorly water soluble antihypertensive drug. The
nanosuspension of felodipine may increase the dissolution
rate of drug to improve its oral bioavailability. The nano-
suspensions were prepared by nanoprecipitation alone and
in combination with ultrasonnication method using ethanol
as solvent and water as antisolvent. The prepared nano-
suspensions were characterised for particle size, zeta
potential, polydispersity index, Scanning electron micros-
copy (SEM), Differential scanning calorimetry (DSC),
X-ray diffraction (XRD) pattern and release behaviour.
The effect of variable concentration of drug and stabiliser,
ultrasonnication, and solvent to antisolvent ratio on the
physical, morphological and dissolution properties of fel-
odipine were studied. The average particle size of felo-
dipine nanoparticles was found to be in the range of
60–330 nm. It was further confirmed by SEM photograph.
The particle size varies with increase in concentration of
drug and stabiliser. The preparations showed negative zeta
potential and polydispersity index in the range of 0.3–0.8.
DSC and XRD studies indicated that the crystallinity of
precipitated felodipine nanoparticles was markedly low-
ered than the pure drug. The dissolution of prepared
felodipine nanoparticles markedly increased as compared
to the original drug. The dissolution profiles of nanosus-
pension formulation showed up to 79.67 % release in 4 h.
It may be concluded that the nanoprecipitation with ultra-
sonnication have potential to formulate homogenous
nanosuspensions with uniform-sized stable nanoparticles of
felodipine. The prepared nanosuspension showed enhanced
dissolution which may lead to enhanced oral bioavailability
of felodipine.
Keywords Nanosuspension  Nanoprecipitation 
Felodipine  Bioavailability
Introduction
The enhancement of the bioavailability of poorly water
soluble drugs is one of the main targets of drug development
during the last decades. Several techniques have been
developed concerning the optimization of the dissolution
rate of these drugs. Such methods include particle size
reduction, solubilization, salt formation and preparation of
solid dispersion systems. Nevertheless, there are several
disadvantages and limitations in the use of these techniques.
Specifically, the particle size reduction technique is prac-
tically limited regarding the minimum size, which could be
achieved, while the production of very fine powders dete-
riorates their flow properties and wettability, while it
advances the development of electrostatic forces, leading to
problematic formulations. The solubilization techniques
correspond to liquid preparations, which usually do not
assure the patient’s acceptability and normally appear to
have poor stability. Salt formation is a complicated process,
while it is not feasible for neutral compounds. In addition,
the dissolution enhancement is not always predictable
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due to the high correlation of the salt’s solubility with the
pH value which appears to be a high variability in the
gastrointestinal tract. (Kakrana et al. 2010).
In fact, for biopharmaceutic class II drugs, the bio-
absorption process is rate-limited by dissolution in gas-
trointestinal fluids. According to the Noyes–Whitney
equation, the dissolution rate of poorly water-soluble drugs
could be increased by reducing the particle size to the
micro or nano-scale thus increasing the interfacial surface
area (Mu¨ller and Peters 1998; Douroumis and Fahr 2006).
The conventional approaches to produce untrafine drug
particles can be divided into top-down and bottom-up
techniques (Keck and Mu¨ller 2006; Rabinow 2004). In the
case of top-down techniques which include jet-milling,
pear/ball milling and high pressure homogenising, the bulk
drugs are comminuted into micro or nano-sized range using
mechanical force (Rasenack et al. 2004). However, these
techniques need high energy input and exhibit some dis-
advantages in practice such as contamination of drugs,
variation of crystal structures, uncontrolled particle mor-
phology, and broad particle size distribution (Keck and
Mu¨ller 2006; Kharb et al. 2006). In the last decade, bottom-
up techniques that rely on dissolving the drug in a solvent
and precipitating it by the addition of a non-solvent,
like supercritical fluid (SCF) technique and liquid precip-
itation, have been widely investigated to obtain ultrafine
drug particles, such as cephradine (Zhong et al. 2005),
cefuroxime axetil (Zhang et al. 2006), danazol (Rogers
et al. 2002; Zhao et al. 2007), ibuprofen (Rasenack et al.
2004), etc.
The nanoprecipitation technique (or solvent displace-
ment method) for nanoparticle manufacture was first
developed and patented by Fessi and co-workers (Fessi
et al. 1988, 1992). This technique presents numerous
advantages, in that it is a straight forward technique, rapid
and easy to perform. The nanoparticle formation is
instantaneous and the entire procedure is carried out in only
one step. Briefly, it requires two solvents that are miscible.
Ideally, both the polymer and the drug must dissolve in the
first one (the solvent), but not in the second system (the
non-solvent). Nanoprecipitation occurs by a rapid desolv-
ation of the polymer when the polymer solution is added to
the non-solvent. Indeed, as soon as the polymer-containing
solvent has diffused into the dispersing medium, the
polymer precipitates, involving immediate drug entrap-
ment. The rapid nanoparticle formation is governed by the
so-called Marangoni effect, which is due to interfacial
turbulences that take place at the interface of the solvent
and the non-solvent and result from complex and cumu-
lated phenomena such as flow, diffusion and surface
tension variations (Quintanar-Guerrero et al. 1998).
Nanoprecipitation often enables the production of small
nanoparticles (100–300 nm) with narrow unimodal
distribution. This technique is mostly suitable for com-
pounds having a hydrophobic nature such as indomethacin,
which is soluble in ethanol or acetone, but has very limited
solubility in water. Consequently, reduced or even zero
drug leakage toward the outer medium led to nanoparticles
with entrapment efficiency values reaching 100 % (Fessi
et al. 1988; Barichello et al. 1999).
Felodipine is a dihydropyridine calcium antagonist
widely used as a potent antihypertensive drug (Saltiel et al.
1988). However, the oral bioavailability of felodipine
extensively metabolised in the gut and the liver, and is
excreted almost entirely as metabolites. About 70 % of
each dose is excreted in the urine; the remainder appears in
the faeces (Dunselman and Edgar 1991; Edgar et al. 1987).
Felodipine is a compound with a strong lipophilic character
whilst it appears as a crystalline powder practically insol-
uble in aqueous solutions (solubility \0.5 mg/l) (Karavas
et al. 2005; Abrahamsson et al. 1994). On the contrary,
Felodipine is rapidly absorbed by the gastrointestinal tract
after dissolution. However, even though it is highly per-
meable through biological membranes (Diez et al. 1991),
the physicochemical characteristics of felodipine indicate
that its dissolution profile is the limiting factor of its bio-
availability (Wingstrand et al. 1990). In order to increase
its dissolution rate, several attempts were carried out in the
past (Kerc et al. 1991; Kim et al. 2005; Lee et al. 2003)
Other methods of solubility enhancement like solid dis-
persions have also been explored for enhancement of sol-
ubility of felodipine (Dong-Han et al. 2005).
The aim of this study is to investigate the possibility of
producing a nanosuspension of felodipine, by controlled
precipitation using ultrasonnication technique to enhance
the dissolution and thereby oral bioavailability of the drug.
The impact of experimental parameters for particle for-
mation including solvent–antisolvent flow rate, drug con-
centrations, type and concentration of stabiliser and stirring
time was studied. Characterization and physical stability of
the obtained nanosuspension were also carried out.
Materials and methods
Preparation of nanoparticles
Felodipine nanoparticles were produced by precipitation–
ultrasonnication technique. The required amount of drug
was completely dissolved in water-miscible solvent. Dif-
ferent concentrations of drug in solvent (20, 40, 60, 80,
100 mg/ml) were used. The obtained drug solution was
then injected into the water containing the stabiliser under
stirring at 1,000 rpm. Precipitation of solid drug particles
occurred immediately upon mixing. The suspension was
then ultrasonicated for 15 min under cold condition.
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Size measurement and zeta potential analysis
The particle size and the polydispersity Index (PI) of the
formed drug particles was measured immediately after
precipitation by dynamic laser light scattering (Zetasizer
Ver. 6.11 Malvern). The measurement was done in tripli-
cate and size Z-Average (d.nm) and the polydispersity
Index PI was reported (Yuancai et al. 2010). The zeta
potential of the preparations was also measured using
(Zetasizer Malvern).
Scanning electron microscopy (SEM)
Particle morphology was observed using scanning elec-
tron microscopy (SEM) JSM-6360 (JEOL Inc., Japan).
The samples’ small drop of the suspension was air dried
followed by oven drying and was fixed on an SEM stub
using double-sided adhesive tape and coated with Au at
20 mA for 6 min through a sputter-coater (Ion sputter
JFC 1100). A scanning electron microscope with a sec-
ondary electron detector was used to obtain digital images
of the samples at an accelerating voltage of 15 kV.
(Yuancai et al. 2010).
Drug entrapment efficiency (DEE)
The freshly prepared nanosuspension was centrifuged at
20,000 rpm for 20 min at 5 C temperature using cool
ultracentrifuge. The amount of unincorporated drug was
measured by taking the absorbance of the appropriately
diluted 25 ml of supernatant solution at 363 nm using UV
spectrophotometer against blank/control nanosuspension.
DEE was calculated by subtracting the amount of free
drug in the supernatant from the initial amount of drug
taken. The experiment was performed in triplicate for
each batch and the average was calculated (Mandal et al.
2010).
The entrapment efficiency (EE %) could be achieved by
the following equation:
Entrapment efficiency %ð Þ ¼ Winitial drug  Wfree drug
Winitial drug
 100
X-ray diffraction studies (XRD)
X-ray diffraction analysis was employed to detect the
effect on crystallinity of precipitated felodipine nanopar-
tilces which was conducted using a XRD-6000 diffrac-
tometer (Shimadzu, Japan). The powder was placed in a
glass sample holder. CuK radiation was generated at
30 mA and 40 kV. Samples were scanned from 10 to 90
with a step size of 0.02 (Martine et al. 1998).
Fourier transforms infrared spectroscopy (FT-IR)
Drug excipients interactions were studied by FTIR spec-
troscopy (Hai-Xia et al. 2009). The spectra were recorded
for Felodipine, HPMC (Hydroxy propyl methyl cellu-
lose), Felodipine–HPMC Physical Mixture (1:5) and the
dried nanoparticles. Samples were prepared in KBr discs
(2 mg drug in 8 mg KBr) with a hydrostatic press at a
force of 8 t cm-2 for 2 min. The scanning range was
450–4,000 cm-1 and resolution was 2 cm-1.
Differential scanning calorimetry (DSC)
The DSC analysis of pure drug, HPMC, Felodipine–HPMC
Physical Mixture (1:5) and the dried nanoparticles was
carried out using Mettler Toledo (Model SW 810) to
evaluate any possible drug–excipients interaction. Samples
(5.5–8 mg) were weighed accurately using a single pan
electronic balance and heated in sealed aluminium pan at
rate of 5 C/min from 25 to 450 C temperature range
under a nitrogen flow of 35 ml/min. (Hany et al. 2009).
In vitro release kinetic experiments
The dialysis membrane diffusion technique was used. One
millilitre of the nanosuspensions was placed in the dialysis
membrane (Mw cutoff 12,000–14,000 Hi-media), fixed in a
Kisery chien apparatus of surface area and receptor volume
of 20 ml. A solvent system of Ethanol–water (50:50) was
used as receptor medium. The entire system was kept at
37 C with continuous magnetic stirring. Samples (1 ml)
were withdrawn from the receptor compartment at prede-
termined time intervals and replaced by fresh medium. The
amount of drug dissolved was determined with UV spec-
trophotometry at 363 nm.
Physical stability study
Three temperature conditions were applied in the stability
study of the nanosuspensions: 4 C (refrigerator), room
temperature and 40 C (Stability Chamber). Physical sta-
bility of the nanosuspensions was evaluated after 6 months
of storage. The measurement of particle size was per-
formed and settling behaviour by visual examination
(Eerdenbrugh et al. 2008).
Results and discussion
Preparation of nanoparticles
Felodipine nanoparticles were produced by precipitation–
ultrasonnication technique. The aqueous phase containing a
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suitable stabiliser has been used as the antisolvent and the
use of different water miscible solvents (ethanol, acetone)
having good solubility of felodipine has been explored as
solvent. The effect of various variables like diffusing drug
concentration, solvent:antisolvent ratio (S:NS), type of
stabiliser, concentration of stabiliser, stirring time and
ultrasonnication has been observed. The results have been
summarised in Table 1.
Acetone and ethanol have been tried as solvent for the
preparations. But acetone-based formulations show aggre-
gation of particles and settling on storage. The viscosity of
the preparation increases indication flocculation behaviour.
Hence acetone has not been used for further studies. The
preparations may require use of suitable stabilisers. Ethanol
as solvent produces very uniform-sized nanoparticles on
precipitation.
From the preliminary studies no specific effect on par-
ticle sizes has been observed at different solvent:antisol-
vent ratios (1:10, 1:15, 1:20). Preparations with S: NS 1:20
were a bit more homogenous, hence were taken for the
preparation as suitable S:NS ratio. The effect of stirring
time (5, 10, 30, 60 min) on the particle size was studied.
No sign of aggregation due to stirring has been observed,
and the particle size does not depend on stirring time.
HPMC and PVA, at various concentrations (0.1, 0.25,
0.5, 1.0 %), have been used as stabiliser for the prepara-
tions. From the preliminary studies, 0.5 % concentration
was found to be optimum for both PVA (poly vinyl alco-
hol) and HPMC. The PVA-based formulations at concen-
tration 0.5 % gave smaller and more uniform nanoparticles
as observed by particle size analysis and SEM whereas
preparations based on 0.5 % HPMC as stabiliser were a bit
bigger and cuboidal in size.
The preparations have been made with different dif-
fusing drug concentration (20, 40, 60, 80, 100 mg/ml). At
lower concentrations of 5 and 10 mg/ml the precipitated
particles were quite bigger and mostly in millimetre range.
The particle size varies with the change in drug concen-
tration. The study indicates that sufficient supersaturation is
required for diffusing drugs to get precipitated in nanop-
articulate range. Preparations with 80 mg/ml diffusing drug
concentration were found to be optimum for PVA-based
formulations whereas in case of HPMC it was found at
40 mg/ml.
The effect of ultrasonnication has been studied since the
preparation obtained by precipitation alone showed less
homogeneity and particles were obtained in bigger size
range with average particles size at 600–800 nm as shown
in Fig. 1a. The particle size was considerably decreased
and more uniform in case of precipitation followed by
ultrasonnication for 15 min under cold condition as shown
in Fig. 1b. Hence, precipitations with ultrasonnication have
been used for further preparations of nanoparticles of
felodipine.
Size measurement and zeta potential analysis
The particle size and the polydispersity Index (PI) of the
formed drug particles was measured immediately after
precipitation by dynamic laser light scattering (Zetasizer
Ver. 6.11Malvern). The average particle size of felodipine
nanoparticles was found to be in the range of 60–330 nm.
The formulations containing 0.5 % HPMC as stabiliser
showed particle size in the range of 320–410 nm at various
drug concentrations. The formulations were homogeneous
as indicated by polydispersity index of 0.5 ± 0.1. The
average particle diameter was found to decrease further in
formulations containing PVA as stabiliser at concentrations
of 0.5 %. The average diameter ranged in between 108 and
191 nm at various drug concentrations. The particle size
distributions were found to be more uniform as the poly-
dispersity index narrowed down to 0.3–0.5. The zeta

















in 4 h (%)
FF1 60 0.15 60.48 0.766 92.2 68.87
FF2 60 0.25 73.09 0.754 89.6 76.8
FF3 60 0.5 108.5 0.49 87.4 79.67
FF4 60 1.0 143.7 0.371 91.1 69.24
FF5 20 0.5 320.2 0.699 78.2 73.1
FF6 40 0.5 310.7 0.624 82.1 74.6
FF7 60 0.5 410.7 0.983 82.6 68.8
FF8 80 0.5 370.6 0.526 84.5 69.4
FF9 20 0.5 172.6 0.530 88.2 73.4
FF10 40 0.5 191.8 0.495 88.7 72.5
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potential of the nanoparticles was found to be negative
which may be due to the presence of terminal carboxylic
groups. High potential values should be achieved to ensure
a high-energy barrier and favour a good stability. The
results have been shown in Table 1.
Drug entrapment efficiency
The formulations showed drug entrapment in the range of
84–92 %. Formulation (FF6) containing drug concentration
80 mg/ml stabilised with PVA showed highest entrapment
up to 92 % w/v. Formulations containing PVA showed
better entrapment in comparison to HPMC. The results
have been shown in Table 1.
Scanning electron microscopy (SEM)
Morphology of precipitated drug particles in the suspension
after air drying followed by oven-drying is shown in
Fig. 2a and b. The drug particles precipitated with the PVA
as stabiliser are spherical in shape and the size ranges from
60 to 200 nm. The particles are discrete and uniform in size
and there is no sign of agglomerations. The drug particles
precipitated with the HPMC as stabiliser are slightly bigger
and spherical and somewhat cuboidal and the size ranges
from 100 to 300 nm.
Differential scanning calorimetry (DSC)
The DSC analysis of pure drug, HPMC, Felodipine–
HPMC Physical Mixture (1:5) and the dried nanoparticles
was carried. The pure drug felodipine showed a melting
point peak at 145 C which was not changed in its
physical mixture (1:5) with HPMC. The DSC thermogram
however showed that after being precipitated as nano-
particles, its melting point was decreased to 133 C,
indicating reduced crystallinity. The results are shown in
Fig. 3.
X-ray diffraction studies (XRD)
The representative X-ray diffraction patterns of the pure
Felodipine powder and oven dried nanosuspensions are
shown in Fig. 4. The figures indicated the changes in the
drug crystal structure. The X-ray patterns of the pure
Felodipine displayed the presence of numerous distinct
peaks at 10.19, 16.51, 20.47, 23.27, 24.51, 25.37,
26.45, and 32.65, which suggested that the drug was
of crystalline form. The precipitated nanoparticles sam-
ples showed the similar diffraction pattern but with
lower peak intensity, suggesting the crystallinity of pre-
cipitated nanoparticles decreased during the precipitation
process.
Fig. 1 a Particle size
distribution of nanoparticles
formed by precipitation without
sonication. b Particle size
distribution of PVA based
nanoparticles formed by
precipitation with sonication.
c Particle size distribution of
HPMC based nanoparticles
formed by precipitation with
sonication. d Zeta potential
measurement of HPMC based
nanoparticles formed by
precipitation with sonication
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Fourier transforms infrared spectroscopy (FT-IR)
Infra red spectra of Felodipine and physical mixture (1:5)
of Felodipine and HPMC and the precipitated nanoparticles
were comparable and the peaks of Felodipine in the
physical mixture are of lower intensity than pure drug.
The characteristic peak of 993, 1,431, 1,672, 2,935 and
3,134 cm-1 which corresponds to C–Cl (aromatic), aro-
matic ring stretch, C=O (ester form), C–H stretch and
heterocyclic secondary amine stretch respectively were
found to be intact in the physical mixture as well as the
formulation which indicates the absence of HPMC and
drug interactions. Very less stretching or broadening of
peaks of drug was observed in mixture form. The results
have been shown in Fig 5.
In vitro release kinetic experiments
It needs to be verified in vitro that nanoparticles were able
to release incorporated drugs to achieve a biological effect.
Membrane diffusion techniques are the most widely used
experimental methods for the study of the in vitro release
profiles of drugs incorporated in nanoparticles. The release
profile of felodipine nanosuspensions in ethanol–water
(50:50) solvent system which shows up to 79.67 % release
in 4 h. The dissolution of prepared felodipine nanoparticles
markedly increased as compared to the original drug.
Fig. 2 a SEM photomicrograph of PVA based felodipine Nanoparticles (X 43,000). Scale bar = 0.5 lm. b SEM photomicrograph of HPMC
based felodipine Nanoparticles (X 27,000). Scale bar = 0.5 lm
Fig. 3 DSC thermograms of (red line) Pure drug felodipine (blue
line) HPMC (green line) Felodipine and HPMC (physical mixture)
(violet line) precipitated felodipine nanoparticles
Fig. 4 X-ray diffraction patterns of (blue line) Pure felodipine drug
(red line) Precipitated felodipine nanoparticles
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The comparative release results of selected formulations
have been shown in Fig 6. Formulations based on PVA
showed better release than that of HPMC as stabiliser.
Physical stability study
The particle size of the formulations after 6 months was
observed. The formulations at 4 C remained stable,
whereas that at room temperature showed slight increase
in particle size. In the case of HPMC formulations, only
those stored at higher temperatures (40 C) exhibited an
increase in mean particle size. The increase in size in the
HPMC formulation stored at 40 C was attributed to
dehydration of the HPMC chains and subsequent loss of
protection of the nanoparticles. The particle size data are
given in Table 2. Sedimentation was observed in all the
conditions but the preparations were easily redispersed on
shaking.
Fig. 5 FTIR spectras of a Pure drug felodipine b HPMC c Precipitated felodipine nanoparticles
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Conclusion
It may be concluded that the nanoprecipitation with ultra-
sonnication have potential to formulate homogenous
nanosuspensions with uniform-sized stable nanoparticles of
felodipine. The reduced particle size and decline in crys-
tallinity of the precipitated particles may enhance the sol-
ubility of felodipine. The study also showed that the
nanosuspension showed enhanced dissolution of felodip-
ine. Since the limited oral bioavailability of felodipine is
due to its poor dissolution hence the increase solubility,
and thereby the dissolution of felodipine in the form of
nanosuspension may enhance the oral bioavailability of
felodipine. The preparations were found to physically sta-
ble with PVA and HPMC as stabiliser.
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